An interventional study of tDCS of dlPFC and Sham Stimulation of dlPFC in Multiple Sclerosis and Fatigue in Multiple Sclerosis, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Charite University, Berlin, Germany.
Among the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 19th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18–60 · Women only
Charite University, Berlin, Germany · Sites in Germany
Ages 18–50 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1
First in 2007; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 53 across the 14 interventional studies, 100 across the 5 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
1 of the studies in Multiple Sclerosis by Charite University, Berlin, Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07183683Charite University, Berlin, GermanyStimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The neurobiological basis of central fatigue in multiple sclerosis remained unclear so far. This study investigates reward-related brain mechanisms, inflammation, and their modulation by non-invasive brain stimulation using fMRI, proteomics, and clinical measures to improve future treatment of central fatigue in MS. In the study, persons suffering from relapsing-remitting MS (RRMS) with vs. without comorbid central fatigue will be included.
The study comprises five experimental visits conducted at Charité University Medicine on five consecutive days (i.e., V1 - V5) and two follow-up visits two (V6) and four (V7) weeks after V5. True or sham anodal transcranial Direct Current Stimulation (tDCS) is applied to the left dorsolateral prefrontal cortex (dlPFC) at the five visits V1 to V5. All primary and secondary outcomes are assessed at V1 and V5.
At V6 and V7, measures of central fatigue are additionally assessed via questionnaires which are send to and back from the patients via mail.
Participants of all groups will participate in all visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men and women
Exclusion Criteria:
MRI
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Medical device: tDCS Stimulation over left dorsolateral prefrontal cortex (DLPFC) for 20 min daily over 5 consecutive days
Device: tDCS of dlPFC
Medical device: Placebo Sham stimulation over left dorsolateral prefrontal cortex (dlPFC) for 20 min daily over 5 consecutive days
Device: Sham Stimulation of dlPFC
Transcranial direct current stimulation over left dorsolateral prefrontal cortex (DLPFC) for 20 min daily over 5 consecutive days at 1200 uA
Sham Stimulation of the dlPFC via tDCS device for 20 minutes on 5 consecutive days
Central fatigue
Assessed with cognitive subscale of with Fatigue Scale for Motor and Cognitive Functions (FSMC): Minimum 20 points, maximum 100 points, higher values denoting worse outcome
Time frame: At enrolment and 4 days, two weeks and four weeks after enrolment
Neurobehavioral markers of effort discounting
Measured in a functional MRI (fMRI) task
Time frame: At enrolment and 4 days after enrolment
Neurobehavioral markers of habit formation
Measured in an fMRI task
Time frame: At enrolment and 4 days after enrolment
White matter integrity MRI measure
Computed as voxel-wise quotients of T1-weighted and T2-weigted anatomical MRI brain scan parameters
Time frame: At enrolment and 4 days after enrolment
Brain age marker
Inferred via machine learning from anatomical T1-weighted brain scan
Time frame: At enrolment and 4 days after enrolment
Whole-brain grey matter fraction
Inferred from anatomical T1-weighted brain MRI scans
Time frame: At enrolment and 4 days after enrolment
Whole-brain volume of focal brain lesions
Inferred from anatomical T2-weighted brain MRI scans
Time frame: At enrolment and 4 days after enrolment
Change in concentration of inflammatory markers
124 blood-derived inflammatory cytokine and chemokine markers determined via an inflammatory panel
Time frame: At enrolment and 4 days after enrolment
Change in cognitive performance
Brief International Cognitive Assessment for MS (BICAMS)
Time frame: At enrolment and 4 days after enrolment
Complementary fatigue markers
Fatigue Severity Scale (FSS), Minimum value 7, Maximum value 63, higher score denoting a worse outcome.
Time frame: At enrolment, and 4 days, two and four weeks after enrolment
Severity of depressive symptoms
Beck Depression Inventory (BDI-II), Minimum value 0, Maximum value 63, higher values denoting worse outcome
Time frame: At enrolment and 4 days after enrolment
Sleep quality
Pittsburgh Sleep Quality Index (PSQI), Minimum Score 0, Maximum Score 21, higher score denoting worse outcome
Time frame: At enrolment and 4 days after enrolment
Severity of anxiety symptoms
Measured on the State-Trait Anxiety index-I (STAI-I), minimum score 20, maximum score 80, higher score denoting worse outcome
Time frame: At enrolment and 4 days after enrolment
Change in Fatigue severity
Visual analogue scale of fatigue (VAS-F), minimum value 1, maximum value 10, higher score denoting worse outcome
Time frame: At enrolment, and 1,2,3,4 days, two and four weeks after enrolment
Plan to share: Yes — Individual participant data that underlie the results of reported articles (text, tables, figures, supplemental data) will be shared after deidentification.
Supporting information: Study protocol
Time frame: Beginning three years after project end
Access criteria: Researchers who provide a methodologically sound proposal.
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Mar 2028, 24 months later.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 24 months is close to that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →